Skip to main content Accessibility help
×
Home
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 2
  • Print publication year: 2015
  • Online publication date: February 2015

27 - ADHD and tic disorders

References

1. FreemanRD.Tourette Syndrome International Database Consortium. Tic disorders and ADHD: answers from a world-wide clinical dataset on Tourette syndrome. Eur Child Adolesc Psychiatry. 2007;16(Suppl 1):15–23. Erratum in: Eur Child Adolesc Psychiatry. 2007;16(8):536.
2. Centers for Disease Control and Prevention (CDC). Prevalence of diagnosed Tourette syndrome in persons aged 6–17 years – United States, 2007. MMWR Morb Mortal Wkly Rep. 2009;58(21):581–5.
3. SteinbergT., Shmuel BaruchS, HarushA, et al. Tic disorders and the premonitory urge. J Neural Transm. 2010;117(2):277–84.
4. PetersonBS, LeckmanJF.The temporal dynamics of tics in Gilles de la Tourette syndrome. Biol Psychiatry. 1998;44:1337–48.
5. CohrsS, RaschT, AltmeyerS, et al. Decreased sleep quality and increased sleep related movements in patients with Tourette’s syndrome. J Neurol Neurosurg Psychiatry. 2001;70:192–7.
6. FindleyDB, LeckmanJF, KatsovichL, et al. Development of the Yale Children’s Global Stress Index (YCGSI) and its application in children and adolescents with Tourette’s syndrome and obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 2003;42:450–7.
7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th edn (DSM-5). Arlington, VA: American Psychiatric Publishing; 2013.
8. World Health Organization. The International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10). Geneva: World Health Organization; 1993.
9. KhalifaN, Von KnorringAL.Prevalence of tic disorders and Tourette syndrome in a Swedish school population. Dev Med Child Neurol. 2003;45:315–19.
10. LinazasoroG, Van BlercomN, de ZárateCO.Prevalence of tic disorder in two schools in the Basque country: results and methodological caveats. Mov Disord. 2006; 21(12):106–9.
11. MasonA, BanerjeeS, EapenV, et al. The prevalence of Tourette syndrome in a mainstream school population. Dev Med Child Neurol. 1998;40:292–6.
12. RobertsonMM, EapenV, CavannaAE.The international prevalence, epidemiology, and clinical phenomenology of Tourette syndrome: a cross-cultural perspective. J Psychosom Res. 2009;67:475–83.
13. KurlanR, McDermottMP, DeeleyC, et al. Prevalence of tics in school children and association with placement in special education. Neurology. 2001;57:1383–8.
14. BlochMH, PetersonBS, ScahillL, et al. Adulthood outcome of tic and obsessive-compulsive symptom severity in children with Tourette syndrome. Arch Pediatr Adolesc Med. 2006;160:65–9.
15. JankovicJ, Gelineau-KattnerR, DavidsonA.Tourette’s syndrome in adults. Mov Disord. 2010;25(13):2171–5.
16. SpencerT, BiedermanJ, WilensT.Attention-deficit/hyperactivity disorder and comorbidity. Pediatr Clin North Am. 1999;46(5):915–27.
17. KhalifaN, Von KnorringAL.Psychopathology in a Swedish population of school children with tic disorders. J Am Acad Child Adolesc Psychiatry. 2006;45(11):1346–53.
18. KurlanR, ComoPG, MillerB, et al. The behavioral spectrum of tic disorders: a community-based study. Neurology. 2002;59(3):414–20.
19. DebesNM, HjalgrimH, SkovL.The presence of comorbidity in Tourette syndrome increases the need for pharmacological treatment. J Child Neurol. 2009;24(12):1504–12.
20. CoffeyB, BiedermanJ, GellerD, et al. Distinguishing illness severity from tic severity in children and adolescents with Tourette’s disorder. J Am Acad Child Adolesc Psychiatry. 2000;39(5):556–61.
21. StorchEA, MerloLJ, LackC, et al. Quality of life in youth with Tourette’s syndrome and chronic tic disorder. J Clin Child Adolesc Psychol. 2007;36(2):217–27.
22. RizzoR, GulisanoM, CaliPV, et al. Long term clinical course of Tourette syndrome. Brain Dev. 2012;34(8):667–73.
23. SukhodolskyDG, Landeros-WeisenbergerA, ScahillL, LeckmanJF, SchultzRT.Neuropsychological functioning in children with Tourette syndrome with and without attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2010;49(11):1155–64.
24. LebowitzR, MotlaghMG, KatsovichL, et al. Tourette syndrome in youth with and without obsessive compulsive disorder and attention deficit hyperactivity disorder. Eur Child Adolesc Psychiatry. 2012;21(8):451–7.
25. BudmanCL, BruunRD, ParkKS, LesserM, OlsonM.Explosive outbursts in children with Tourette’s disorder. J Am Acad Child Adolesc Psychiatry. 2000;39(10):1270–6.
26. CarterAS, O’DonnellDA, SchultzRT, et al. Social and emotional adjustment in children affected with Gilles de la Tourette’s syndrome: associations with ADHD and family functioning. J Child Psychol Psychiatry. 2000;41(2):215–23.
27. BurdL, FreemanRD, KlugMG, KerbeshianJ.Tourette syndrome and learning disabilities. BMC Pediatr. 2005;5:34.
28. SpencerT, BiedermanJ, HardingM, et al. Disentangling the overlap between Tourette’s disorder and ADHD. J Child Psychol Psychiatry. 1998;39(7):1037–44.
29. PierreBC, NolanE, GadowK, et al. Comparison of internalizing and externalizing symptoms in children with attention-deficit hyperactivity disorder with and without comorbid tic disorder. J Dev Behav Pediatr. 1999;20(3):170–6.
30. GormanDA, ThompsonN, PlessenKJ, et al. Psychosocial outcome and psychiatric comorbidity in older adolescents with Tourette syndrome: controlled study. Br J Psychiatry. 2010;197(1):36–44.
31. RobertsonMM, OrthM.Behavioral and affective disorders in Tourette syndrome. Adv Neurol. 2006;99:39–60.
32. HaddadAD, UmohG, BhatiaV, RobertsonMM.Adults with Tourette’s syndrome with and without attention deficit hyperactivity disorder. Acta Psychiatr Scand. 2009;120(4):299–307.
33. SpencerTJ, BiedermanJ, FaraoneS, et al. Impact of tic disorders on ADHD outcome across the life cycle: findings from a large group of adults with and without ADHD. Am J Psychiatry. 2001;158:611–17.
34. ZhuY, LeungKM, LiuPZ, et al. Comorbid behavioral problems in Tourette’s syndrome are positively correlated with the severity of tic symptoms. Aust N Z J Psychiatry. 2006;40(1):67–73.
35. HydeTM, AaronsonBA, RandolphC, et al. Relationship of birth weight to the phenotypic expression of Gilles de la Tourette’s syndrome in monozygotic twins. Neurology. 1992;42:652–8.
36. MathewsCA, BimsonB, LoweTL, et al. Association between maternal smoking and increased symptom severity in Tourette’s syndrome. Am J Psychiatry. 2006;163(6):1066–73.
37. PringsheimT, LangA, KurlanR, PearceM, SandorP.Understanding disability in Tourette syndrome. Dev Med Child Neurol. 2009;51(6):468–72.
38. MotlaghMG, KatsovichL, ThompsonN, et al. Severe psychosocial stress and heavy cigarette smoking during pregnancy: an examination of the pre- and perinatal risk factors associated with ADHD and Tourette syndrome. Eur Child Adolesc Psychiatry. 2010;19(10):755–64.
39. SwainJE, ScahillL, LombrosoPJ, et al. Tourette syndrome and tic disorders: a decade of progress. J Am Acad Child Adolesc Psychiatry. 2007;46(8):947–68.
40. WolfSS, JonesDW, KnableMB, et al. Tourette syndrome: prediction of phenotypic variation in monozygotic twins by caudate nucleus D2 receptor binding. Science. 1996;273:1225–7.
41. PetersonBS, ChoiHA, HaoX, et al. Morphologic features of the amygdala and hippocampus in children and adults with Tourette syndrome. Arch Gen Psychiatry. 2007;64(11):1281–91.
42. AmatJA, BronenRA, SalujaS, et al. Increased number of subcortical hyperintensities on MRI in children and adolescents with Tourette’s syndrome, obsessive-compulsive disorder, and attention deficit hyperactivity disorder. Am J Psychiatry. 2006;163(6):1106–8.
43. PriceRA, KiddKK, CohenDJ, et al. A twin study of Tourette syndrome. Arch Gen Psychiatry. 1985;42:815–20.
44. ScharfJM, YuD, MathewsCA, et al. Genome-wide association study of Tourette’s syndrome. Mol Psychiatry. 2013;18:721–8.
45. BlochMH, PanzaKE, Landeros-WeisenbergerA, LeckmanJF.Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Adolesc Psychiatry. 2009;48(9):884–93.
46. SteingardR, BiedermanJ, SpencerT, WilensT, GonzalezA.Comparison of clonidine response in the treatment of attention-deficit hyperactivity disorder with and without comorbid tic disorders. J Am Acad Child Adolesc Psychiatry. 1993;32(2):350–3.
47. ScahillL, ErenbergG, BerlinCM, Jr., et al.; Tourette Syndrome Association Medical Advisory Board: Practice Committee. Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx. 2006;3(2):192–206. Review.
48. Boon-yasidhiV, KimYS, ScahillL.An open-label, prospective study of guanfacine in children with ADHD and tic disorders. J Med Assoc Thai. 2005;88(8):S156–62.
49. ChappellPB, RiddleMA, ScahillL, et al. Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette’s syndrome: preliminary clinical experiences. J Am Acad Child Adolesc Psychiatry. 1995;34:1140–6.
50. LoweTL, CohenDJ, DetlorJ, KremenitzerMW, ShaywitzBA.Stimulant medications precipitate Tourette’s syndrome. JAMA. 1982;247(12):1729–31.
51. GadowKD, SverdJ, SprafkinJ, NolanEE, EnzorSN.Efficacy of methylphenidate for attention-deficit hyperactivity disorder in children with tic disorder. Arch Gen Psychiatry. 1995;52(6):444–55.
52. Tourette’s Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology. 2002;58(4):527–36.
53. CastellanosX, GieddJ, EliaJ, et al. Controlled stimulant treatment of ADHD and comorbid Tourette’s syndrome: effects of stimulant and dose. J Am Acad Child Adolesc Psychiatry. 1997;36:589–96.
54. AllenAJ, KurlanRM, GilbertDL, et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology. 2005;65(12):1941–9.
55. SpencerTJ, SalleeFR, GilbertDL, et al. Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome. J Atten Disord. 2008;11(4):470–81.
56. SpencerT, BiedermanJ, KermanK, SteingardR, WilensT.Desipramine treatment of children with attention-deficit hyperactivity disorder and tic disorder or Tourette’s syndrome. J Am Acad Child Adolesc Psychiatry. 1993;32(2):354–60.
57. SpencerT, BiedermanJ, CoffeyB, et al. A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2002;59:649–56.
58. SingerHS, BrownJ, QuaskeyS, et al. The treatment of attention-deficit hyperactivity disorder in Tourette’s syndrome: a double-blind placebo-controlled study with clonidine and desipramine. Pediatrics. 1995;95(1):74–81.
59. BiedermanJ, BaldessariniRJ, WrightV, KneeD, HarmatJS.A double-blind placebo controlled study of desipramine in the treatment of ADD: I. Efficacy. J Am Acad Child Adolesc Psychiatry. 1989;28(5):777–84.
60. BruggemanR, Van der LindenC, BuitelaarJK, et al. Risperidone versus pimozide in Tourette’s disorder: a comparative double-blind parallel-group study. J Clin Psychiatry. 2001;62(1):50–6.
61. SalleeFR, KurlanR, GoetzCG, et al. Ziprasidone treatment of children and adolescents with Tourette’s disorder: a pilot study. J Am Acad Child Adolesc Psychiatry. 2000;39:292–9.
62. BudmanC, CoffeyBJ, ShechterR, et al. Aripiprazole in children and adolescents with Tourette disorder with and without explosive outbursts. J Child Adolesc Psychopharmacol. 2008;18(5):509–15.
63. LyonGJ, SamarS, JummaniR, et al. Aripiprazole in children and adolescents with Tourette’s disorder: an open-label safety and tolerability study. J Child Adolesc Psychopharmacol. 2009;19(6):623–33.
64. MurphyTK, MutchPJ, ReidJM, et al. Open label aripiprazole in the treatment of youth with tic disorders. J Child Adolesc Psychopharmacol. 2009;19(4):441–7.
65. YooH, JoungYS, LeeJS, et al. A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette’s disorder. J Clin Psychiatry. 2013;78(8):e722–80.
66. GabbayV, BabbJS, KleinRG, et al. A double-blind, placebo-controlled trial of ω-3 fatty acids in Tourette’s disorder. Pediatrics. 2012;129(6):e1493–500.
67. KurlanR, CrespiG, CoffeyB, et al.; Pramipexole for TS Trial Investigators. A multicenter randomized placebo-controlled clinical trial of pramipexole for Tourette’s syndrome. Mov Disord. 2012;27(6):775–8.
68. ScottBL, JankovicJ, DonovanDT.Botulinum toxin injection into vocal cord in the treatment of malignant coprolalia associated with Tourette’s syndrome. Mov Disord. 1996;11(4):431–3.
69. NeunerI, PodollK, JanouschekH, et al. From psychosurgery to neuromodulation: deep brain stimulation for intractable Tourette syndrome. World J Biol Psychiatry. 2009;10(4 Pt 2):366–76.
70. AzrinNH, NunnRG.Habit-reversal: a method of eliminating nervous habits and tics. Behav Res Ther. 1973;11(4):619–28.
71. PiacentiniJ, WoodsDW, ScahillL, et al. Behavior therapy for children with Tourette disorder: a randomized controlled trial. JAMA. 2010;303(19):1929–37.